drugset / Trial / NCT06706284
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
Phase 4
Recruiting
50 enrolled
Marzieh Salehi
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
Non-randomizedParallel-groupSingle-blindTreatment
Summary
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.
Timeline
- Start
- 2025-04-11
- Primary completion
- 2028-09-01
- Completion
- 2029-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Semaglutide | Peptide | 2 mg | — |